| Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease |
31 |
| Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases |
29 |
| Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis |
15 |
| NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands |
13 |
| Sickle cell disease, sickle trait and the risk for venous thromboembolism: a systematic review and meta-analysis |
12 |
| Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation |
12 |
| TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease |
11 |
| The diagnosis and treatment of venous thromboembolism in asian patients |
11 |
| Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy |
11 |
| Human blood platelets and viruses: defense mechanism and role in the removal of viral pathogens |
9 |
| Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study |
8 |
| Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study |
7 |
| Venous thromboembolism prophylaxis may cause more harm than benefit: an evidence-based analysis of Canadian and international guidelines |
7 |
| Predictive risk factors of venous thromboembolism (VTE) associated with peripherally inserted central catheters (PICC) in ambulant solid cancer patients: retrospective single Centre cohort study |
6 |
| Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk |
6 |
| COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study |
6 |
| Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study |
5 |
| Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study |
5 |
| Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study |
5 |
| Down-regulation of platelet adhesion receptors is a controlling mechanism of thrombosis, while also affecting post-transfusion efficacy of stored platelets |
5 |
| Activated protein C plays no major roles in the inhibition of coagulation or increased fibrinolysis in acute coagulopathy of trauma-shock: a systematic review |
5 |
| A brief review on resistance to P2Y(12) receptor antagonism in coronary artery disease |
5 |
| Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill |
4 |
| Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis |
4 |
| Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! |
4 |
| Circulating activated protein C levels are not increased in septic patients treated with recombinant human soluble thrombomodulin |
3 |
| Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience |
3 |
| Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study |
3 |
| Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients |
3 |
| International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) |
3 |
| Chemoprophylaxis in addition to mechanical prophylaxis after total knee arthroplasty surgery does not reduce the incidence of venous thromboembolism |
3 |
| Thrombotic thrombocytopenic purpura (TTP)-like syndrome in the HIV era |
3 |
| Could sodium imbalances predispose to postoperative venous thromboembolism? An analysis of the NSQIP database |
3 |
| Prognostic assessment for patients with cancer and incidental pulmonary embolism |
2 |
| Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature |
2 |
| Circulating histone H3 levels in septic patients are associated with coagulopathy, multiple organ failure, and death: a single-center observational study |
2 |
| Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial |
2 |
| Effects of glycemic control and hypoglycemia on Thrombus formation assessed using automated microchip flow chamber system: an exploratory observational study |
2 |
| Decreased antithrombin activity in the early phase of trauma is strongly associated with extravascular leakage, but not with antithrombin consumption: a prospective observational study |
2 |
| Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel |
1 |
| Poor outcomes associated with antithrombotic undertreatment in patients with atrial fibrillation attending Gondar University Hospital: a retrospective cohort study |
1 |
| Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study |
1 |
| Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency |
1 |
| Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series |
1 |
| Implementation of an acute DVT ambulatory care pathway in a large urban centre: current challenges and future opportunities |
1 |
| Combination of acquired von Willebrand syndrome (AVWS) and Glanzmann thrombasthenia in monoclonal gammopathy of uncertain significance (MGUS), a case report |
0 |
| Guideline compliance for bridging anticoagulation use in vitamin-K antagonist patients; practice variation and factors associated with non-compliance |
0 |
| Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease |
0 |
| Genotypic and phenotypic character of Chinese neonates with congenital protein C deficiency: a case report and literature review |
0 |
| Arteriolar vs. valvular thrombosis: Pick your evil! |
0 |
